Liver Fibrosis in Zambian HIV-HBV Co-infected Patients

• Status: Active, not recruiting
• Trial end date: 2024-08-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study the investigators will determine risk factors for liver fibrosis among HIV-HBV co-infected patients in Lusaka, Zambia, and assess the long-term effectiveness of antiretroviral drugs in the prevention and/or reduction of liver disease.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Alabama at Birmingham; University of North Carolina, Chapel Hill
• Collaborators: Fogarty International Center of the National Institute of Health; John E. Fogarty International Center (FIC); National Institutes of Health (NIH)
• Treatments: Anti-HIV Agents

Criteria

Inclusion Criteria:

• Age 18 years or older

• HIV-infected

• HBV-infected, defined as any single positive HBsAg assay

• Naïve to antiretroviral therapy or currently participating in HIV/HBV co-infection in IeDEA-SA

Exclusion Criteria:

• Unable or unwilling to provide informed consent

• Planning to relocate out of Lusaka district